Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2024-06-30, filed 2024-08-14, with 10 holding rows worth $592,420,772.

Accession
0000899140-24-000887
Filed
2024-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2024

A holdings report, 10 entries on the cover page, a total value of $592,420,772 stated on the cover page (in dollars after the unit check, H1), rows summing to $592,420,772 with VALUE read as dollars as filed, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BIOGEN INC COM09062X103Stock643,000$149,060,260dollars as filed
INNOVIVA INC45781M101COM7,277,000$119,342,800dollars as filed
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK16,390,000$106,862,800dollars as filed
Gilead Sciences,Inc.375558103COM1,103,282$75,696,178dollars as filed
CYTOKINETICS INC23282W605COM NEW1,110,000$60,139,800dollars as filed
NEUROCRINE BIOSCIENCES INC64125C109COM410,483$56,511,195dollars as filed
AMARIN CORP PLC023111206SPONS ADR NEW24,850,623$17,097,229dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock1,094,168$6,761,958dollars as filed
VOR BIOPHARMA INC929033108COM618,000$618,000dollars as filed
REGULUS THERAPEUTICS INC75915K309COM185,183$330,552dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000899140-24-000887this filing2024-08-14acceptance time not in the bulk data set